Grifols holder Mason Capital against potential Brookfield deal
Mason Capital opposes Grifols sale to Brookfield Asset Management, raising concerns about the potential acquisition in the ...
How Trump’s win and the latest interest-rate cut will affect you as a consumer, homeowner and investor
In the Ratings Game column, Steve Gelsi looked into an upgrade of Bank of America Corp.’s stock by Citi Research analyst Keith Horowitz, driven by the analyst’s expectations for large-cap banks in ...
NBC Washington7h
Philadelphia Phillies capital raise values the team at around $3 billion
The Philadelphia Phillies recently raised close to $500 million in capital from three new investors, according to two people ...
NBC New York7h
3 ways President-elect Donald Trump's next term may impact student loan borrowers
Most federal student loan borrowers weren't making payments when Former President Donald Trump left office in 2021, due to ...
Fed meeting recap: Powell ‘feeling good' about economy, says Trump can't legally fire him
The Federal Reserve trimmed interest rates by a quarter point, bringing the target rate range to 4.5% to 4.75%. Fed Chair ...
Healthy Returns: Weight loss drug race heats up with pill data from Viking Therapeutics, AstraZeneca
AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...
bovnews12h
What’s Driving Viking Therapeutics Inc (VKTX) Stock’s 9.91% Surge Over the Past Month?
H.C. Wainwright has recently reiterated Viking Therapeutics Inc (VKTX) stock to Buy rating, as announced on November 4, 2024, according to Finviz. Earlier, on September 11, 2024, JP Morgan had ...
4 Reasons Why Buying Viking Therapeutics Stock Right Now Is a Smart Move
When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...
Promising Growth Potential for Keros Therapeutics Driven by Robust Clinical Pipeline and Upcoming Data Releases
Leerink Partners analyst Thomas Smith has reiterated their bullish stance on KROS stock, giving a Buy rating yesterday. Thomas Smith’s ...
Business Insider18h
Oppenheimer Sticks to Its Hold Rating for Moderna (MRNA)
The company’s shares closed yesterday at $50.28. Olson covers the Healthcare sector, focusing on stocks such as Jasper Therapeutics, Amgen, and Viking Therapeutics. According to TipRanks, Olson has an ...